Biomarker Chip for Osteoarthritis

骨关节炎生物标记芯片

• 批准号: 6551356
• 负责人: Stephen Francis Kingsmore
• 金额: $ 10万
• 依托单位: MOLECULAR STAGING, INC.
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-09-11 至 2004-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6551356
• 关键词: antibody; biomarker; cartilage; clinical research; cytokine; diagnosis design /evaluation; human tissue; microarray technology; musculoskeletal disorder diagnosis; osteoarthritis; physiologic bone resorption; synovial fluid

DESCRIPTION (provided by applicant): Osteoarthritis (OA) is the most prevalent musculo-skeletal disease in the older adult population, characterized by chronic pain and life long disability. The current 'gold standard' for diagnosis of OA is radiology, but radiological changes occur relatively late in the disease after the bone tissue changes responsible for the pain and disability have already taken place. A diagnostic test that uses biomarkers of OA for early detection would be useful in early diagnosis and treatment, ameliorating symptoms and potentially lessening disability. The general goal of this project is to produce a microarray for detecting proteins in serum that are biomarkers of OA including cytokines and products of cartilage & bone catabolism In order to achieve sufficient sensitivity, this microarray will utilize a novel proprietary technology, rolling circle amplification, for signal amplification. The RCA-enabled microarray will offer the benefits of multiplexing (measuring approximately 100 analytes simultaneously), reduced sample volume (only 15 ul/assay), high-throughput, and exceptional sensitivity (ca. 10 pg/mI). Initial studies will be done with serum from patients with OA and appropriate controls using our current cytokine chip. We also will identify other reagents as potentially useful biomarkers for OA with the aim of designing an OA chip.

描述（由申请人提供）：骨关节炎（OA）是老年人群中最常见的肌肉骨骼疾病，其特征是慢性疼痛和终身残疾。目前诊断OA的“金标准”是放射学，但放射学变化发生在疾病发生相对较晚的骨组织变化后，导致疼痛和残疾已经发生。使用OA的生物标志物进行早期检测的诊断测试将有助于早期诊断和治疗，改善症状并可能减轻残疾。本项目的总体目标是制备用于检测血清中蛋白质的微阵列，这些蛋白质是OA的生物标志物，包括细胞因子和软骨和骨软骨的产物。为了达到足够的灵敏度，该微阵列将利用新颖的专有技术，滚环扩增，用于信号放大。RCA使能的微阵列将提供多路复用（同时测量约100种分析物）、减少样品体积（仅15 μ l/测定）、高通量和卓越灵敏度（约100 μ l/测定）的优点。10 pg/ml）。将使用我们目前的细胞因子芯片对OA患者的血清和适当的对照进行初步研究。我们还将确定其他试剂作为OA的潜在有用的生物标志物，目的是设计OA芯片。